Ella Thompson

Utility of clinical comprehensive genomic characterization for diagnostic categorization in patients presenting with hypocellular bone marrow failure syndromes

Piers Blombery, Lucy C Fox, Georgina L Ryland, Ella R Thompson, Jennifer Lickiss, Michelle McBean, Satwica Yerneni, David Hughes, Anthea Greenway, Francoise Mechinaud, Erica M Wood, Graham J Lieschke, Jeff Szer, Pasquale Barbaro, John Roy, Joel Wight, Elly Lynch, Melissa Martyn, Clara Gaff, David Ritchie

Journal article  |  2021  |  Haematologica: the hematology journal

Bone marrow failure (BMF) related to hypoplasia of haematopoietic elements in the bone marrow is a heterogeneous clinical entity w..

Clonal independence of JAK2 and CALR or MPL mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing.

Ella R Thompson, Tamia Nguyen, Yamuna Kankanige, Paul Yeh, Michael Ingbritsen, Michelle McBean, Timothy Semple, Gisela Mir Arnau, Kate Burbury, Nora Lee, Amit Khot, David Westerman, Piers Blombery

Journal article  |  2021  |  Haematologica: the hematology journal

Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia

Donia M Moujalled, Fiona C Brown, Giovanna Pomilio, Natasha S Anstee, Veronique Litalien, Ella R Thompson, Thomas Morley, Sarah MacRaild, Chong C Chua, SéBastien Banquet, Maia Chanrion, Ana-Leticia Maragno, Marie Schoumacher, Marco J Herold, Guillaume Lessene, Olivier Geneste, David CS Huang, Andrew W Roberts, Piers Blombery, Andrew Wei

Journal article  |  2020  |  Blood

Background: Recent randomized trials have demonstrated improvements in overall survival (OS) for the BCL-2 inhibito..

BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia

Piers Blombery, Ella R Thompson, Xiangting Chen, Tamia Nguyen, Mary Ann Anderson, David Alan Westerman, John F Seymour, Constantine S Tam, Michael A Dengler, David CS Huang, Andrew Wei, Andrew W Roberts

Journal article  |  2020  |  Blood

Venetoclax (Ven) is an effective element of treatments for chronic lymphocytic leukemia (CLL) with high response rates observed in..

A synonymous GATA2 variant underlying familial myeloid malignancy with striking intrafamilial phenotypic variability

Lucy C Fox, Michelle Tan, Anna L Brown, Peer Arts, Ella Thompson, Georgina L Ryland, Jennifer Lickiss, Hamish S Scott, Nicola K Poplawski, Kerry Phillips, Neil A Came, Paul James, Stephen B Ting, David S Ritchie, Jeff Szer, Christopher N Hahn, Anthony Schwarer, Piers Blombery

Journal article  |  2020  |  British Journal of Haematology

Detection of an IGH-BRAF fusion in a patient with BRAF Val600Glu negative hairy cell leukemia

Ella R Thompson, Kenneth JC Lim, James A Kuzich, Michelle McBean, David Westerman, Constantine S Tam, Piers Blombery

Journal article  |  2020  |  Leukemia & Lymphoma

Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax

Piers Blombery, Ella R Thompson, Nguyen Tamia, Richard W Birkinshaw, Jia-Nan Gong, Xiangting Chen, Michelle McBean, Rachel Thijssen, Thomas Conway, Mary Ann Anderson, John F Seymour, David A Westerman, Peter E Czabotar, David CS Huang, Andrew W Roberts

Journal article  |  2020  |  Blood

Severe chemotherapy toxicity in a 10-year-old with T-acute lymphoblastic lymphoma harboring biallelic FANCM variants

Georgina L Ryland, Lucy C Fox, Virginia Wootton, Ella R Thompson, Jennifer Lickiss, Alison H Trainer, Paddy Barbaro, Morag Whyte, David Ritchie, Piers Blombery

Journal article  |  2020  |  Leukemia & Lymphoma

Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax

Piers Blombery, Ella Thompson, Nguyen Tamia, Xiangting Chen, Michelle McBean, Richard W Birkinshaw, Peter E Czabotar, Rachel Thijssen, Mary Ann Anderson, John F Seymour, David Alan Westerman, David CS Huang, Andrew W Roberts

Conference Proceedings  |  2019  |  Blood

BTK Leu528Trp-a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib

Sasanka M Handunnetti, Chloe Pek Sang Tang, Nguyen Tamia, Xing Zhou, Ella Thompson, Hanzi Sun, Haimei Xing, Bo Zhang, Yin Guo, Lesley Ann Sutton, Paolo Ghia, Richard Rosenquist, Lydia Scarfo, Silvia Bonfiglio, John F Seymour, Mary Ann Anderson, Andrew W Roberts, David CS Huang, Ye Liu, Chan Y Cheah, et al.

Conference Proceedings  |  2019  |  Blood